Bay­er dou­bles down on ra­dio­ther­a­py with ac­qui­si­tions of 2 tiny biotech play­ers built around re­search from Cor­nell

With #AS­CO21 just days away, Swiss drug­mak­er No­var­tis is set to un­veil late-stage da­ta for its high­ly tout­ed ra­di­oli­gand, po­ten­tial­ly chart­ing a new course for the once-dis­re­gard­ed field. Now, Bay­er is look­ing to chase its own slice of the pie, sign­ing its name to an ear­ly-stage pact based on sci­ence out of Cor­nell.

Bay­er will pay an undis­closed sum to snatch up No­ria Ther­a­peu­tics and PS­MA Ther­a­peu­tics, two tiny biotechs built around ra­dio­ther­a­py re­search from the Weill Cor­nell Med­ical Col­lege in NYC, to ex­pand its ra­dio­phar­ma­ceu­ti­cal pipeline, the Ger­man gi­ant said Thurs­day.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER